$2.48
0.60% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US8808811074
Symbol
TERN
Sector
Industry

Terns Pharmaceuticals Inc Stock price

$2.49
-0.90 26.55% 1M
-5.71 69.63% 6M
-3.05 55.05% YTD
-4.15 62.50% 1Y
-0.46 15.59% 3Y
-14.51 85.35% 5Y
-14.51 85.35% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.07 2.73%
ISIN
US8808811074
Symbol
TERN
Sector
Industry

Key metrics

Market capitalization $217.37m
Enterprise Value $-139.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.98
P/B ratio (TTM) P/B ratio 0.63
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-101.87m
Free Cash Flow (TTM) Free Cash Flow $-70.45m
Cash position $358.16m
EPS (TTM) EPS $-1.13
P/E forward negative
Short interest 7.47%
Show more

Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Terns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Terns Pharmaceuticals Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Terns Pharmaceuticals Inc forecast:

Buy
71%
Hold
29%

Financial data from Terns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.90 0.90
2% 2%
-
-0.90 -0.90
2% 2%
-
- Selling and Administrative Expenses 30 30
20% 20%
-
- Research and Development Expense 70 70
10% 10%
-
-101 -101
1% 1%
-
- Depreciation and Amortization 0.90 0.90
2% 2%
-
EBIT (Operating Income) EBIT -102 -102
1% 1%
-
Net Profit -89 -89
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Terns Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about 21 hours ago
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees un...
Neutral
GlobeNewsWire
14 days ago
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., Marc...
Positive
The Motley Fool
25 days ago
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals...
More Terns Pharmaceuticals Inc News

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Head office United States
CEO Amy Burroughs
Employees 59
Founded 2017
Website www.ternspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today